Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

South Carolina Attorney Gerneral: Lone fight With Pfizer Will Net More Money

By Pharmaceutical Processing | September 8, 2009

CHARLESTON, S.C. (AP) — As the only state that didn’t accept part of a $2.3 billion settlement from pharmaceutical giant Pfizer Inc. over illegal sales tactics, South Carolina stands to gain more in the end, state Attorney General Henry McMaster said. McMaster said his office has been negotiating its own settlement with the drug maker since the spring, The Post and Courier of Charleston reported in a story published Saturday. “It’s more work for us, but we will get multiple times more money for the taxpayer than if we would have joined the group,” McMaster told the newspaper. The attorney general brushed aside any suggestions that being the only state outside the settlement could be risky, saying the strategy was in South Carolina’s best interest. McMaster, a Republican who also is running for governor next year, refused to say how much the state wants from Pfizer and said there is no way to know how much South Carolina could have received had it been involved in the settlement. A lawsuit hasn’t been filed, and a spokesman for Pfizer refused to talk about the situation. Federal prosecutors called Pfizer a repeating corporate cheat for its illegal drug promotions that plied doctors with free golf, massages, and resort junkets. The settlement announced Wednesday includes $331 million to be split between 49 states and the District of Columbia, with most of the money going toward Medicaid. State lawyers are negotiating with Pfizer on behalf of Medicaid and the State Employees Insurance Plan, McMaster said. “We’re confident that the taxpayers of South Carolina will do much better if we fight these claims as we are doing than if we had taken the other route, which was to participate in a group,” he said.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards